Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial

Table 1

Baseline demographic and clinical characteristics in the patients with aMCI (ITT population).

	Herbal therapy	Donepezil
	Age (year)	62.67 (7.96)		63.80 (8.25)	0.332
Gender
Male	88 (40.9)	46 (43.0)	0.724
Female	127 (59.1)	61 (57.0)
Education
Primary school	40 (18.6)	26 (24.3)	0.233
Longer than middle school	175 (82.4)	81 (75.7)
Race (%)
Han	207 (96.3)	106 (99.1)	0.281
Others	8 (3.7)	1 (0.9)
MMSE score	27.38 (1.35)	27.11 (1.59)	0.140
HAMD score	6.44 (3.27)	6.39 (3.51)	0.910
GDS stage
Stage 1	0 (0)	1 (0.9)	0.843
Stage 2	101 (47.0)	47 (43.9)
Stage 3	114 (53.0)	59 (55.1)
ADAS-cog	14.81 (6.39)	15.14(6.10)	0.650
DSR	10.03 (2.97)	9.90 (3.25)	0.719

Data are mean (SD) or number (%). value for the comparison between the donepezil group and herbal group and the nontreated group. ITT = intent-to-treat. ADAS-cog = Alzheimer’s Disease Assessment Scale-cognitive subscale; DSR = Delayed Story Recall; HAMD = Hamilton Depression Rating scale; HIS = Hachinski Ischemia scale; GDS = Global Deterioration Scale; MMSE = Mini-Mental State Examination.